COVID-19 mortality is strongly associated with the development of severe pneumonia and
acute respiratory distress syndrome with the worst outcome resulting in cytokine release …

Abstract The coronavirus disease 2019 (COVID-19) triggered by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) erupted in Hubei Province of China in December …

The dysfunction of the renin-angiotensin system (RAS) has been observed in coronavirus
infection disease (COVID-19) patients, but whether RAS inhibitors, such as angiotensin …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive-sense,
single-stranded RNA virus that causes the potentially lethal Covid-19 respiratory tract …

In light of the outbreak of the 2019 novel coronavirus disease (COVID-19), the international
scientific community has joined forces to develop effective treatment strategies. The …

In response to infectious and, in some instances, noninfectious insults, the affected
tissues/cells of the host undergo inflammation. However, uncontrolled inflammation could be …

Although myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) has a specific and
distinctive profile of clinical features, the disease remains an enigma because causal …

The ongoing severe acute respiratory syndrome pandemic caused by the novel coronavirus
2 (SARS-CoV-2) is associated with high morbidity and mortality rates, and it has created a …

Myocardial damage, by different noxious causes, triggers an inflammatory reaction driving
post-injury repair mechanisms and chronic remodelling processes that are largely …

Renin–angiotensin system (RAS) blockers are extensively used worldwide to treat many
cardiovascular disorders, where they are effective in reducing both mortality and morbidity …